$SCYX News

Last published 2d ago

2d agoSCYXGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - SCYNEXIS INCEarnings Call TranscriptsI'm Vamil Devan, one of the biopharma analysts here at Guggenheim. Pleased to join us now. Next in this room, we have the team from Synexis, David Angulo up here, the CEO of the company. We do have a few slides we're goi
6d agoSCYXSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026Awarded BARDA contract providing up to
1w agoSCYXSCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation ConferenceGlobeNewswireJERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the
2w agoSCYXSCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal DiseasesGlobeNewswireIntravenous SCY-247 was generally well tolerated in healthy participants, with no drug-related serious adverse eventsOnce-daily intravenous doses of 50 mg or higher achieved exposures at or above the target identified
3w agoSCYXSCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeekGlobeNewswireJERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for
1mo agoSCYXSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & DevelopmentGlobeNewswireJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare
2mo agoSCYXSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial OfficerGlobeNewswireJERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare
2mo agoSCYXSCYNEXIS to Participate in Upcoming Investor ConferencesGlobeNewswireJERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with
2mo agoSCYXSCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireJERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with
3mo agoSCYXSCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireInitiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2
4mo agoSCYXSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)GlobeNewswireJERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiation of a Phase 1
5mo agoSCYXSCYNEXIS Announces One-for-Eight Reverse Stock SplitGlobeNewswireJERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today
6mo agoSCYXSCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept
6mo agoSCYXSCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireJERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases
7mo agoSCYXPoxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 MillionBusiness WirePXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant polycystic kidney
7mo agoSCYXSCYNEXIS Announces $40.0 Million Private PlacementGlobeNewswireJERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address severe rare diseases
7mo agoSCYXSCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)GlobeNewswirePXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progressionA Phase 2 proof-of-concept study of SCY-770 in
8mo agoSCYXSCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireSCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and
8mo agoSCYXSCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247GlobeNewswireJERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,
8mo agoCERO CRVO SCYXCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel
9mo agoSCYXSCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)GlobeNewswireJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
9mo agoSCYXSCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247GlobeNewswireThe QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal
10mo agoSCYXSCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RequirementGlobeNewswireJERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
11mo agoSCYXSCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKGlobeNewswireGSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low
11mo agoSCYXScynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal InfectionsGlobeNewswireFive-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of
1y agoSCYXSCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireSCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK's
1y agoSCYXSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO StudyGlobeNewswireSCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO studyThe payment from
1y agoSCYXSCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)GlobeNewswireNo safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the
1y agoSCYXSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)GlobeNewswireOral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations
1y agoSCYXSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025GlobeNewswireJERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
1y agoSCYXSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireFirst new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary
1y agoSCYXSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyGlobeNewswireFirst new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six
1y agoSCYXSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireIbrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently
1y agoSCYXSCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)GlobeNewswireJERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,
1y agoSCYXSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireThe Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted by the European
1y agoSCYXSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsGlobeNewswireJERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireClinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3
2y agoSCYXSCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual SummitGlobeNewswireJERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024GlobeNewswireJERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireJERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireClinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we expect
2y agoSCYXSCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study ReportsGlobeNewswireJERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSCY-247's IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal
2y agoSCYXSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)GlobeNewswireIn vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains
2y agoSCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)GlobeNewswireJERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,
2y agoSCYXSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSCY-247's IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received
2y agoSCYXSCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology ConferenceGlobeNewswireJERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis ConferenceGlobeNewswireIn vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B
2y agoSCYXSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, ItalyGlobeNewswireJERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
2y agoSCYXSCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against SCYNEXIS, Inc. ("Scynexis" or the "Company")...